66 results about "Amyloid fibril" patented technology

Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disesase, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.

Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.

Methods for the production of monoclonal antibodies specific to conformational epitope(s) of a prefibrilar aggregate(s) which contribute to amyloid fibril formation in human or animal subjects who suffer from amyloid diseases (e.g. Alzheimer's Disease) and the hybridomas and monoclonal antibodies produced therefrom. Also, the use of such monoclonal antibodies in the immunization of human or animal subjects against Alzheimer's Disease or other amyloid diseases and/or for the diagnosis or detection of Alzheimer's Disease or other amyloid diseases. The monoclonal antibodies may be administered concomitantly or in combination with anti-inflammatory agents, such as gold or gold containing compounds, to decrease neural inflammation associated with amyloid diseases (e.g. Alzheimer's Disease).

The invention relates to methods for measuring conformational changes and self-assembly/aggregation of proteins, especially the formation of amyloid fibrils, using conjugated polyelectrolytes. The conjugate polyelectrolyte is exposed to the protein whereby the conjugated polyelectrolyte and the protein of interest interact, and a change of a property of the polyelectrolyte in response to conformational changes of the protein is observed. The detected change is used to determine different conformations of the protein, especially the formation of amyloid fibrils.

Methods and compositions are presented that inhibit fibril formation and/or bring about disassembly of pre-formed fibrils. Compositions include peptides with short beta-strands with two faces: one that can bind to beta-amyloids through hydrogen bonds, and one which blocks propagation of hydrogen bonding needed to form fibrils. Thus, short congeners of the fibril protein containing N-methyl amino acids or esters are provided for the inhibition of fibril formation and for the disassembly of pre-existing or pre-formed fibrils. Specific aspects address beta-amyloid fibrils; prion mediated fibrils; Huntington protein fibrils. Methods for screening for potential fibril inhibitors and disassemblers, diagnostic analysis and treatments are provided.

Described is a new class of small molecule inhibitors of amyloid beta protein (Abeta) aggregation, based on apomorphine. These molecules target the nucleation phase of Abeta self-assembly and interfere effectively with aggregation of Abeta 1-40 into amyloid fibrils in vitro as determined by transmission electron microscopy, Thioflavin T (ThT) fluorescence, and velocity sedimentation. Structure-activity studies using apomorphine analogues demonstrate that 10,11-dihydroxy substitutions of the D ring are preferred for the inhibitory effectiveness of these aporphines, and that methylation of these hydroxyl groups reduces their inhibitory potency. The ability of these small molecules to inhibit Abeta amyloid fibril formation appears to be linked to their ability to undergo auto-oxidation in solution, implicating an auto-oxidation product as the active Abeta inhibitor. Sedimentation velocity and electron microscopy studies demonstrate that apomorphine and analogues facilitate oligomerization of Abeta into short nonfibrillar soluble assemblies, but inhibit Abeta fibrillization.

The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited:

New conjugates comprising fragments of amyloid proteins, which may be used in vaccines for the treatment, prevention and/or amelioration of diseases associated with deposition of amyloid proteins, such as, e.g. Alzheimers disease. Methods for treating, preventing and/or ameliorating amyloid-related diseases, by administering a conjugate comprising fragments of an amyloid protein to a subject in need thereof, thereby enabling the production of antibodies in the subject. Antibodies—being capable of interacting with pathological regions within an amyloid protein, and thereby preventing e.g. the formation of amyloid fibrils, plaques and/or deposits, and methods for passive immunization wherein an antibody as described above is administered to a subject in need thereof. Furthermore is provided specific fragments of the C-terminal part of amyloid beta (1-42), that when administered to a mammal generates antibodies, which specifically targets the soluble form of the highly amyloidogenic amyloid beta (1-42).

Methods and compositions for treating biofilms and diseases associated with amyloidosis such as Alzheimer's, Parkinson's and Huntington's disease, and Type 2 diabetes, by destroying amyloid fibrils in a two-step treatment are disclosed. The first step consists of binding to the amyloid fibril an intercalating molecule with a negatively charged group such as Congo red. The second step consists of adding metal ions, such as silver, gold(I), copper(I), palladium or lead ions or metal colloids of silver or gold, which destabilize the amyloid-dye complex. This process results in a disintegration of the fibril into peptide monomers and small aggregates of monomers.

A method of preventing or treating an amyloid-β-related disease in an individual, the method comprising administering to an individual in need thereof an effective amount of a first therapeutic agent for preventing or treating an amyloid-β-related disease, and a second A therapeutic agent, the second therapeutic agent being (i) a peptide or peptidomimetic compound that modulates amyloid-beta fibril formation or induces a prophylactic or therapeutic immune response against amyloid-beta fibril formation, or (ii) Immune system modulator that prevents or inhibits amyloid-beta fibril formation.

An amyloid fibril formation inhibitor comprising a compound represented by the following general formulae (I) to (III):

wherein

• • Q is —C(═O)—;
  • X is —C(═O)—, —NH—C(═O)—;
  • Y is —(CH₂)_m—;
  • Z is —(CH₂)_n—;
  • R₁, R₂, and R₃ are each independently a hydrogen atom, an alkyl group, a hydroxyalkyl group, an alkylaminoalkyl group; and
  • R₄ is an amino group, an alkylamino group or the like;
  • or a pharmaceutically acceptable salt thereof or a solvate thereof.

Methods and pharmaceutical compositions for treatment of amyloid deposition diseases using chimeric (e.g., mouse-human) antibody are disclosed, including a method for treating amyloid deposition diseases with cardiac involvement by administering pharmaceutical compositions comprising a chimeric anti-amyloid fibril antibody. The methods herein can improve myocardial function in patients diagnosed with light chain amyloid light chain amyloidosis (ALA) having a cardiac involvement in as little as three weeks after treatment.

The present invention provides IGIV and IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The present invention also provides methods for obtaining IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The IGIV recognizes amyloid fibrils and partially denatured amyloidogenic precursor polypeptides. They are useful for treating diseases and conditions associated with amyloid deposition. The IGIV of the present invention also are useful for diagnosing and detecting amyloid deposition.

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of familial amyloid polyneuropathy may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of transthyretin-related hereditary amyloidosis, neurodegenerative diseases, amyloidosis, neuropathic pain, amyloid fibril formation and cardiomyopathy related diseases.

The present invention provides new antifibrillogenic agents and peptides, compositions and cells containing same, compositions that bind to same, effective therapeutics for preventing or delaying the progression of, e.g., Alzheimer's disease and diabetes, methods for optimizing antifibrillogenic agents, and methods of using the antifibrillogenic agents, peptides, compositions, and cells of the invention for detecting and/or inhibiting amyloid fibril formation.

Methods and related immunoglobulin peptides and fragments thereof are disclosed that enhance the cell-mediated immune response of a patient to deposits of amyloid fibrils. These methods exploit the opsonizing effect of antibodies directed toward amyloid material or its component parts.

A method of dissolving or disrupting pre-formed or pre-deposited amyloid fibrils and/or inhibiting amyloid formation, deposition, accumulation, or persistence in Alzheimer's disease, prion diseases and/or other amyloidoses in a mammalian subject is disclosed. In the method a therapeutically effective amount of nattokinase is administered.

The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited:

Methods for disrupting amyloid fibrils in a subject, comprising combining an effective amount of a β-2 microglobulin fibril disrupting compound with a medium associated with the subject, are disclosed. The invention also relates to combining the β-2 microglobulin fibril disrupting compound ex vivo with the blood during dialysis treatment of an animal. It also relates to methods for determining which compounds are effective at disrupting amyloid fibrils in a medium.

The invention relates to methods for obtaining antibodies that recognize amyloid protofibrils and antibodies that recognize one or more amyloid protofibrils. Also provided are methods of using the antibodies to prevent or inhibit amyloid disease in a subject, to diagnose amyloid disease in a subject, and to detect amyloid protofibrils in a sample.